Clinical trials: Opioid-Related Disorders
Opiate Substitution Treatment, Opioid-Related Disorders
Use of a GLP-1R Agonist to Treat Opioid Use Disorder
This research is being done to find out if liraglutide (brand name is Saxenda®) can safely and effectively reduce craving for opioids in patients with opioid use disorder, a primary factor contributing to early relapse.
- Trial name
- NCT04199728
- Testing
- Liraglutide Pen Injector
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Milton S. Hershey Medical Center
Drug Effect, Rib Fractures
Trial of Injected Liposomal Bupivacaine vs Bupivacaine Infusion After Surgical Stabilization of Rib Fractures
Rib fractures represent a common injury pattern this is highly associated with patient morbidity and mortality, as pain control remains a challenge.
- Conditions
- Drug Effect, Rib Fractures, Rib Trauma, Surgical Procedure, Unspecified
- Trial name
- NCT03305666
- Testing
- Liposomal bupivacaine injection, Bupivacaine indwelling catheter
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Denver Health and Hospital Authority
Opioid-use Disorder, Cocaine Use Disorder
Feasibility and Validation of a Standard Phenotyping Assessment Battery
The overall goal of this project is to collect preliminary data on psychosocial measures and behavioral performance comparing individuals with Opioid Use Disorder, Cocaine Use Disorder, dual diagnosis of Opioid and Cocaine Use…
- Conditions
- Opioid-use Disorder, Cocaine Use Disorder, Marijuana Use Disorder, Healthy Controls
- Trial name
- PhAB (NCT03495869)
- Where
- United States
- Volunteers
- 368 people
- Sponsor
- Virginia Commonwealth University
Alcoholism, Opiate Dependence
ALK21-006EXT: Long-term Safety of Medisorb® Naltrexone (VIVITROL®) in Alcohol- or Opioid-dependent Adults (Extension of Study ALK21-006 [NCT01218997])
This was a multicenter extension of Alkermes' Study ALK21-006 (NCT01218997) designed to assess the long-term safety of repeat monthly doses of naltrexone long-acting injection.
- Trial name
- NCT00156936
- Testing
- Medisorb naltrexone 380 mg, Oral naltrexone to Medisorb naltrexone 380 mg
- Volunteers
- 108 people
- Sponsor
- Alkermes, Inc.
Opioid Dependence, Acute Opioid Withdrawal Syndrome
Efficacy, Safety and Dose-Response Study Followed by Open-Label Study of Lofexidine Treatment of Opioid Withdrawal
The purpose of this study is to look at the efficacy and safety for lofexidine hydrochloride, an alpha-2 adrenergic agonist under development for the treatment of acute withdrawal from short-acting opioids.
- Trial name
- NCT01863186
- Testing
- Lofexidine HCl, Open Label Lofexidine HCL
- Where
- 18 sites in United States
- Volunteers
- 603 people
- Sponsor
- USWM, LLC (dba US WorldMeds)
Opioid-use Disorder
SUBLOCADE Rapid Initiation Study
This study is to evaluate the safety and tolerability of initiating SUBLOCADE™ treatment following a shorter period of transmucosal (TM) buprenorphine treatment.
- Trial name
- NCT03993392
- Testing
- TM buprenorphine, SUBLOCADE
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Indivior Inc.
Opioid Dependence
Glutamatergic Modulation to Facilitate Naltrexone Initiation in Opioid Dependence
Opioid dependence is a substantial problem associated with significant morbidity and mortality. Extended-release naltrexone has been found effective at reducing opioid use and maintaining abstinence, but its use has been limited…
- Trial name
- NCT02437344
- Testing
- CI-581aa, Naltrexone titration and XR-NTX initiation
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- New York State Psychiatric Institute
Covid-19, Substance Use
Leveraging Social Networks to Increase COVID-19 Testing Uptake
This two-year project will adapt and conduct a trial examining the ability of two recruitment strategies, chain-referral and credible messenger, to reach those who use opioids and other substances in order to increase their…
- Conditions
- Covid-19, Substance Use, Opioid Use
- Trial name
- NCT04873401
- Testing
- Chain-referral, Credible Messenger
- Where
- United States
- Volunteers
- 498 people, healthy volunteers welcome
- Sponsor
- New York State Psychiatric Institute
Opioid Use Disorder
Impact of Bridge™ Device to Treat Opioid Withdrawal Symptoms
The purpose of this prospective study is to investigate the efficacy of the Bridge™ device in reducing the symptoms of opioid withdrawal in a blind comparison to a sham device.
- Trial name
- NCT05924945
- Testing
- Bridge™ active device
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Masimo Corporation
Opiate Antagonist Overdose, Opioid-Related Disorders
Naloxone Auto-injector as a Universal Precaution for Patients With Opioid Use Disorder
The purpose of this pilot-study is to to distribute naloxone auto-injector in a "Universal Precaution" manner to patients with opioid substance use disorder.
- Trial name
- NCT02669901
- Testing
- Naloxone Auto-Injector
- Where
- United States
- Volunteers
- 395 people, healthy volunteers welcome
- Sponsor
- University of New Mexico
Opioid Induced Constipation
Evaluation of the Efficacy and Safety of ADL5945 for the Treatment of Opioid-induced Constipation in Adults Taking Opioid Therapy for Chronic Noncancer Pain
Morphine and related opioid analgesics are known to slow gastrointestinal (GI) motility and reduce intestinal secretion through their binding to μ opioid receptors (MORs) within the GI tract.
- Trial name
- NCT01207427
- Testing
- ADL5945 0.1 mg, ADL5945 0.25 mg
- Volunteers
- 131 people
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Hepatitis C, Opioid-Related Disorders
The Kentucky Viral Hepatitis Treatment Study
The overarching goal of the Kentucky Viral Hepatitis Treatment Project (KeY Treat) is to increase hepatitis C virus (HCV) treatment access and delivery in a rural Appalachian community, which is in the midst of the…
- Conditions
- Hepatitis C, Opioid-Related Disorders, Injection Drug Use
- Trial name
- KeY Treat (NCT03949764)
- Testing
- Sofosbuvir/velpatasvir (Epclusa®)
- Where
- United States
- Volunteers
- 380 people
- Sponsor
- Jennifer Havens
Opioid Use Disorder
Study of the BIOPIN 6 Naltrexone Implant in Healthy Adults
The purpose of this study is to evaluate the safety and blood levels of a medicine, naltrexone, contained within an implant in healthy volunteers age 18 to 65 years.
- Trial name
- NCT06216132
- Testing
- BIOPIN-6 Active Implant with Naltrexone
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Akyso Therapeutics, LLC
Opioid Dependence
Re-entry XR-NTX for Rural Individuals With Opioid Use Disorder
The overall aim of this R34 proposal is to examine the feasibility, acceptability, and short-term outcomes associated with an innovative service delivery model to increase adherence to extended-release naltrexone (XR-NTX) during…
- Trial name
- NCT03447743
- Testing
- XR-NTX community location
- Where
- United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- Michele Staton
Opioid Use Disorder
A Study to Assess the Effect of a Single Dose of ASP8062 on the Multiple Dose Safety, Tolerability and Pharmacokinetics of Buprenorphine/Naloxone in Participants With Opioid Use Disorder
The primary purpose of this study was to assess the safety and tolerability of multiple doses of buprenorphine/naloxone alone and buprenorphine/naloxone in combination with a single dose of ASP8062.
- Trial name
- NCT04447287
- Testing
- ASP8062, buprenorphine/naloxone
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Opioid Use Disorder
Auricular Acupressure as a Non-Opioid Adjuvant in Opioid Tolerant Patients
The purpose of this study is to determine if the addition of auricular acupressure to the typical pharmacological regimen given to patients on the chronic pain/addiction service will lower pain scores and decrease pain medication…
- Trial name
- NCT05711537
- Testing
- Auricular Acupressure with Vaccaria 600t ear seeds
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Wake Forest University Health Sciences
Heroin Addiction
Methadone Maintenance for Prisoners
This five-year study examines the benefits of methadone maintenance treatment initiated in prison and continued in the community to male offenders who were previously, but not currently, heroin-dependent.
- Trial name
- MMP (NCT00378079)
- Testing
- Counseling Only, Counseling + Transfer, Counseling + Methadone
- Where
- United States
- Volunteers
- 211 people, healthy volunteers welcome
- Sponsor
- Friends Research Institute, Inc.
Opioid Dependence
A Study of Adult Outpatients With Opioid Dependence Transitioned From a Daily SL Buprenorphine to Probuphine® Subdermal Implants
The primary objective of the study is to demonstrate maintenance of treatment efficacy when transferring adult outpatients with opioid dependence, who are clinically stabilized on 8 mg or less of sublingual (SL) buprenorphine…
- Trial name
- PRO-814 (NCT02180659)
- Testing
- sublingual buprenorphine tablets, Buprenorphine implant
- Volunteers
- 177 people
- Sponsor
- Titan Pharmaceuticals
Opioid-use Disorder
The Effect of Buprenorphine Continuation for Patients With Opioid Use Disorder
There is limited guidance on the optimal management of buprenorphine perioperatively and both buprenorphine discontinuation and continuation are acceptable standards of care.
- Trial name
- NCT04981678
- Testing
- Buprenorphine
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- MaineHealth
Opioid Dependence
The Separate and Combined Effects of Vivitrol and Opiate Abstinence Reinforcement in the Treatment of Opioid Dependence
In this 5-year study, the investigators propose to evaluate the separate and combined effects of the FDA-approved formulation of extended release naltrexone (Vivitrol®) and employment-based reinforcement of opiate abstinence in…
- Trial name
- NCT01556425
- Testing
- Vivitrol, Employment-based opiate abstinence reinforcement, Usual Care Control
- Where
- United States
- Volunteers
- 84 people
- Sponsor
- Johns Hopkins University